Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Leoben – page 33

426 clinical trials in Leoben, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Leoben at a glance
426
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

426 trials in Leoben

Open in trial search

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Study on Ropeginterferon Alfa-2b for Patients with Essential Thrombocythemia Intolerant or Refractory to Other Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ropeginterferon ALFA-2B
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Study on Tacrolimus Dosing for Stable Adult Kidney Transplant Patients in the First Year After Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Medical University Of Vienna

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Study on the Safety and Effectiveness of MK-5475 for Adults with Pulmonary Hypertension and COPD

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Frespaciguat
  • Sponsor:Merck Sharp & Dohme LLC

Study on Growth Hormone Deficiency: Comparing Effects of Continuing vs. Stopping Somatropin Treatment in Pubertal Children with Isolated Growth Hormone Deficiency

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somatropin
  • Sponsor:University College London

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Leoben

What the registry says about research in the country

01 Breast Cancer Research

Advanced clinical trials focusing on hormone receptor-positive breast cancer treatments, including studies of novel therapies for patients with high-risk disease profiles.

  • Node-positive ER+ HER2- breast cancer
  • Advanced breast cancer treatments
  • Endocrine therapy combinations

Multiple studies evaluating innovative therapeutic approaches for improving patient outcomes in early and advanced stages.

02 Lymphoma Studies

Comprehensive research into various types of lymphoma, examining new treatment combinations and comparing their effectiveness to standard therapies.

  • Follicular lymphoma
  • Diffuse Large B-cell Lymphoma
  • Hodgkin Lymphoma

Investigations focus on improving treatment responses while minimizing side effects.

03 Multiple Myeloma Research

Innovative trials exploring multiple myeloma treatments, including maintenance therapy approaches and combination treatments for both newly diagnosed and relapsed cases.

  • Newly diagnosed multiple myeloma
  • Relapsed/Refractory multiple myeloma
  • Combination therapy approaches

Studies aimed at improving treatment outcomes for various stages of the disease.

04 Leukemia & Other Blood Cancers

Research focusing on chronic lymphocytic leukemia and related blood disorders, evaluating novel therapeutic combinations.

  • Recurrent CLL treatments
  • Novel drug combinations
  • Treatment optimization

Trials designed to improve treatment outcomes for patients with recurring disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.